You need to know in phase I if your promising drug candidate may have any harmful effect on human reproduction or development. The answer could ultimately make the difference between approval, approval with warnings, or no approval at all. That calls for experience across the range of human reproduction and development, as well as an understanding of the possibilities along all routes of administration and pharmacokinetics of your chemical compound.

Enter Envigo. We have more than 40 years of experience in the field of reprotoxicology and a huge breadth of experience with both traditional pharmaceuticals and biologicals. We offer our drug development customers a full comprehensive package of reprotoxicology studies for registration and market authorization. We also offer consultancy services in reproductive studies and reproductive pathology. All in our laboratories which are fully AAALAC accredited.

Expand All Tabs
  • Study designs for pharmaceuticals
  • Dosing by all conventional routes
  • Extensive, proven behavioral testing
  • Fetal pathology including Wilson’s sectioning and microdissection techniques, staining for bone and cartilage
  • Computer-assisted sperm assessment (CASA)
  • Specialist pathology of male and female reproductive organs

When you partner with Envigo, you can be confident that your program is being conducted by our highly experienced Reprotoxicology Department team of study directors and senior scientists. Our senior staff is supported by dedicated inhalation specialists, behavioral specialists, animal technicians with special reprotoxicology training, repro necropsy specialists and fetal pathologists. More than half of our department has over 10 years of relevant experience. All at your disposal.

The future of inhaled medications and inhalation technology

[Webinar] De-risking drug development: in vitro strategies that add value to your molecule